Market Overview

FDA Approves Allergan's Ozurdex, Rejects Levadex

Share:
Related AGN
How To Invest In An Aging World With The 'Live Long & Prosper' ETF
RBC Analyst Says 'Buy The Spread' On Allergan-Pfizer Deal
Pfizer names leadership team for combined organization after Allergan buy consummated (Seeking Alpha)

The FDA on Monday approved Allergan's (NYSE: AGN) diabetic macular edema (DME) drug Ozurdex.

Allergan's drug Levadex, a migraine treatment, was rejected by the FDA.

Wells Fargo analyst Larry Biegelsen is projecting a positive outcome for Allergan with its latest stage in development. With few cases of inflammation in DARPin, Biegelsen views DARPin as a plus, in comparison with Roche's Lucentis having none. Wells Fargo has an Outperform rating on Allergan and a price target in the range of $182 to $183.

Leerink analyst Seamus Fernandez says additional delay to Levadex is “frustrating,” removing $30 million of sales from 2014 and raises concerns on long-term peak sales.

Shares of Allergan are down 2.2 percent.

Latest Ratings for AGN

DateFirmActionFromTo
Dec 2015Leerink SwannMaintainsOutperform
Nov 2015Leerink SwannMaintainsOutperform
Oct 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Larry Biegelsen Leerink Seamus Fernandez Wells FargoAnalyst Color News FDA Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters